FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Takeda NDA for Eosinophilic Esophagitis Drug Accepted

[ Price : $8.95]

FDA accepts for priority review a Takeda Pharmaceutical NDA for Eohilia (budesonide oral suspension) for treating eosinophilic eso...

Professors Say Too Few Reviewers on Pfizer Covid Vaccine

[ Price : $8.95]

Two university professors question FDAs decision to assign only one reviewer to several core scientific areas in the Pfizer Covid-...

Vaccine Panel Recommends EUA for Moderna Covid Vaccine

[ Price : $8.95]

An FDA advisory committee votes to recommend an Emergency Use Authorization for Modernas investigational Covid-19 vaccine (mRNA-12...

Guide on Generic Drug Controlled Correspondence

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Controlled Correspondence Related to Generic Drug Developme...

Guide on Dry Eye Drug Development

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Dry Eye: Developing Drugs for Treatment.

Info Collection on State Enforcement Notifications

[ Price : $8.95]

Federal Register notice: FDA seeks comments on an information collection extension entitled State Enforcement Notifications 21 CF...

Rhythm Pharma Granted Priority Review Voucher

[ Price : $8.95]

Federal Register notice: FDA announces the issuance of a priority review voucher to Rhythm Pharmaceuticals related to its rare ped...

Generic Drug Controlled Correspondence Guidance

[ Price : $8.95]

FDA publishes a guidance on how generic drug manufacturers can submit controlled correspondence to FDA seeking generic drug develo...

Priority Review Voucher Awarded to Eiger BioPharm

[ Price : $8.95]

Federal Register notice: FDA issues of a priority review voucher to Eiger BioPharmaceuticals that is related to its rare pediatric...

FDA Advisors Back Greater Entresto Use

[ Price : $8.95]

FDA advisors back an expanded indication for Novartis heart failure drug Entresto but cant specify a patient group.